Anti-MDA-5 Ab (CADM-140) (RDL)
Also known as: Anti-140 kDa peptide (CADM-140) antibody, Anti-melanoma differentiation-associated 5 (MDA5) antibody, Antibody for clinically amyopathic dermatomyositis (CADM)
Use
Anti-MDA5 antibodies are present in 7-35% of adult DM. Clinical features consist of absent or mild muscle symptoms (CADM), rapidly progressive ILD, specific mucocutaneous features of skin ulcerations and papules, oral ulcerations, and arthritis.
Special Instructions
To avoid delays in turnaround time, especially when ordering multiple tests on frozen samples, it is advised to submit separate frozen specimens for each requested test.
Limitations
This test was developed and its performance characteristics were determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration, which may limit its acceptance or the interpretation of its results in certain clinical settings. The performance and results should be interpreted in the context of the overall clinical picture, and laboratories are advised to adhere to local regulatory requirements when using this assay.
Methodology
Immunoassay (ELISA)
Biomarkers
LOINC Codes
- 88725-7
- 103691-2
Result Turnaround Time
7-10 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.3 mL
Container
Red-top tube or gel-barrier tube
Collection Instructions
Separate serum from cells within one hour of collection. Transfer to a plastic transport tube before shipping.
Storage Instructions
Refrigerate or freeze.
Causes for Rejection
Grossly hemolyzed; bacterial contamination; lipemic specimen; icteric specimen; non-serum specimen types
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 7 days |
| Refrigerated | 14 days |
| Frozen | 60 days |